PF-07872437

PF-07872437 is an investigational multivalent pneumococcal conjugate vaccine (PCV) candidate developed by Pfizer. It is part of an expanded vaccine regimen designed to provide broader protection against *Streptococcus pneumoniae* infections compared to existing vaccines like Prevenar 20. The vaccine utilizes conjugate technology, where purified capsular polysaccharides from various pneumococcal serotypes are covalently linked to a carrier protein (typically CRM197) to enhance the immune response, particularly in infants and young children. PF-07872437 is currently being evaluated in Phase 3 clinical trials to assess its safety, tolerability, and immunogenicity in healthy infants, serving as a potential next-generation successor in Pfizer's pneumococcal vaccine portfolio.